Close Menu
New York Examiner News

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    British hackers face prison for GTA 6 data breach and crypto thefts | TechCrunch

    November 18, 2026

    GTA 6: How To Easily Find Story Missions

    November 18, 2026

    All About Lainey Wilsons Husband Devlin Duck Hodges

    November 18, 2026
    Facebook X (Twitter) Instagram
    New York Examiner News
    • Home
    • US News
    • Politics
    • Business
    • Science
    • Technology
    • Lifestyle
    • Music
    • Television
    • Film
    • Books
    • Contact
      • About
      • Amazon Disclaimer
      • DMCA / Copyrights Disclaimer
      • Terms and Conditions
      • Privacy Policy
    New York Examiner News
    Home»Technology»MiLaboratories gets $10M for a platform play to accelerate genomic research
    Technology

    MiLaboratories gets $10M for a platform play to accelerate genomic research

    By AdminOctober 10, 2024
    Facebook Twitter Pinterest LinkedIn WhatsApp Email Reddit Telegram
    MiLaboratories gets $10M for a platform play to accelerate genomic research

    [ad_1]

    Advances in DNA sequencing and the vast amounts of genomic data being produced by next-generation sequencing (NGS) technology have created a startup opportunity to build software for biologists so they can more easily analyze this big data and take the next leap. It could help when it comes to developing new vaccines, cancer treatments and so on.

    For the last four years, MiLaboratories, a San Francisco-based startup with an R&D facility in Bilbao, Spain, has been building a computational biology platform to make it easier for biologists to process, analyze and aggregate their data. It incorporates features like data visualization and generative AI to boost usability.

    Its platform is also designed to be a marketplace for other scientists so that they can distribute more specialized computation tools in the form of apps to keep expanding the utility for the genomics research community. MiLaboratories target scientists whose skillsets span biology, computer science and math — so-called bioinformaticians.

    “It’s a ‘no code’ style approach for biologists and we also release an [open source] SDK — software development kit — allowing bioinformaticians to build real applications,” CEO Stan Poslavsky tells TechCrunch.

    “During my and our founders’ scientific career, we saw a huge inefficiency . . . in how modern therapies, how modern drugs, are developed,” he explains. “Because of this friction between the data — the big data, generated by the biologists, the sequencing data — and the data analysis which is not available for them.”

    While there are “thousands” of software programs and tools that can do analysis of NGS data, he says most have been developed within academia, where the focus tends to be on utility rather than usability.

    There’s also a need for biologists to aggregate and integrate results from multiple analyses, he says. “In a unified picture, allowing you to understand what’s going on. And that’s the place where our platform helps dramatically,” he suggests.

    The startup hopes its platform will free up bioinformaticians from being called upon to deal with the grunt work of genomic data processing so these multidisciplinary scientists can apply their skillset to the more complex tasks of building algorithms that might help advance cutting-edge science.

    “Bioinformaticians are actually spending a lot of time just doing a monkey job of running the software for biologists,” says Poslavsky. “To process this data, you need to have Linux machines, go over SSH, run complicated software tools to get the analysis done and get the insight from the data.”

    “[A doctor] has no skills to do this on Linux, on HPC [high performance computing] cluster, because he has other things to do. And that’s what most bioinformaticians in the companies and academia are doing, actually, just this monthly job of running the tools.”

    MiLaboratories founding team, with Stan Poslavsky second from leftImage Credits:MiLaboratories

    On Thursday, MiLaboratories officially took the wraps off its SDK, Platforma.bio, which lets third-party developers contribute apps — although it’s been in alpha and beta testing for several years. (Poslavsky says “around 300 labs” have been using the beta, and “around 20” apps have been made available through the platform, so far.)

    “The first applications that are available in the platform are built around our biological and bioinformatic applications, which are very popular . . . [with] companies and people involved in immune therapy developments. But we already have . . . a good selection of collaborations and people willing to bring their applications on the platform, both from academia and from the industry,” he adds.

    The 2021-founded startup is also announcing a $10 million Series A funding round to continue development, with a focus on investing in community building.

    “The key reason for raising money is just to plug more hands into the development of our platform. We are hiring more engineers. We are hiring what is called developer advocates, who are propagating the technology around — primarily — the academic community, because most bioinformatics software is developed in academia.”

    “For the upcoming year [we will] focus on the propagation of the technology around the community, and engaging community to build their apps, to wrap their existing software, to deliver them through the platform,” he adds.

    MiLaboratories’ Series A is led by Madrid-based Kfund, with participation from Acrobator Ventures, EGB Capital, Courtyard Ventures, Somersault Ventures, Speedinvest and Ten13.

    Commenting in a statement, Miguel Arias, general partner of Kfund, said: “Investing in platforms that bridge the gap between developers (in this case bioinformaticians) and business users (in this case biologists) is at the core of what we want to do in our fund. There is tremendous potential in democratizing access to complex data enabling the delivery of immunological insights.”

    MiLaboratories offers its software for free to academics but it’s also taking revenue via a paid model for commercial users. Per Poslavsky the startup is approaching 100 paying customers at this stage.

    “Many of the big pharma companies — like Moderna, Bristol-Myers Squibb — they are our customers,” he notes, adding: “We have revenue — good revenue — allowing us to not be so dependent on venture money.”

    At the start of 2022, the startup raised a $2.5 million seed round. It also previously took in a small pre-seed from a few angels.

    Discussing the challenges of developing the computational biology platform, Poslavsky says the staggering amount of data being generated by NGS meant startup had to pay very careful attention to ensuring processing efficiency to avoid generating “crazy costs”.

    “The amount of data generated in the space are actually, well, crazy,” he emphasizes. “Big pharma companies, our customers . . . they have petabytes of genetic data generated so far. So that’s huge scale.”

    MiLaboratories has developed what Poslavsky couches as a “very sophisticated” and “mathematically proven” technology which allows for many sorts of calculations to be performed in “a very optimized way.” He suggests this tech — which it has patented — enables the platform to reach 10x efficiency compared to some other types of computational workflow.

    “That’s a very important thing. It’s hidden from the eyes of the biologist — because the valuable proposition for the biologist is ‘I want to click buttons and get insight’ — but it’s very important for the business owners.”

    Competition wise, Poslavsky names Seqera (and its Nextflow software) as the closest rival — in terms of popularity and value proposition. There are also open source tools for NGS processing, such as Galaxy, but MiLaboratories reckons its platform offers researchers a more accessible route to data insights.

    [ad_2]

    Original Source Link

    Share. Facebook Twitter Pinterest LinkedIn WhatsApp Email Reddit Telegram
    Previous ArticleHow hurricanes like Milton spawn tornadoes
    Next Article CBS News staff told not to refer to Jerusalem as being in Israel: Report

    RELATED POSTS

    British hackers face prison for GTA 6 data breach and crypto thefts | TechCrunch

    November 18, 2026

    Uber and Ziplines drone delivery service takes off in Texas, with dozens of cities to follow | TechCrunch

    November 17, 2026

    US tightens AI chip export controls to deter Chinese companies from accessing compute remotely | TechCrunch

    November 16, 2026

    Where was Nvidias security team? | TechCrunch

    November 15, 2026

    Amazons new Kindle Colorsoft is a premium e-reader with a premium price | TechCrunch

    November 14, 2026

    Uber confirms hackers stole thousands of drivers license information in data breach | TechCrunch

    November 13, 2026
    latest posts

    British hackers face prison for GTA 6 data breach and crypto thefts | TechCrunch

    Two British hackers are facing lengthy prison sentences for separate hacks as part of their…

    GTA 6: How To Easily Find Story Missions

    November 18, 2026

    All About Lainey Wilsons Husband Devlin Duck Hodges

    November 18, 2026

    RAYE announces second London BST Hyde Park 2027 show due to phenomenal demand

    November 18, 2026

    Electric Forest Planning 2027 Festival After Two Deaths at 2026 Event

    November 18, 2026

    Elizabeth Hurley, 61, Wows In See-Through Red Dress With Billy Ray By Her Side

    November 18, 2026

    New Mystery and Thriller Books to Read | November 17 – NewInBooks

    November 17, 2026
    Categories
    • Books (1,592)
    • Business (6,481)
    • Events (85)
    • Film (6,453)
    • Lifestyle (4,504)
    • Music (6,587)
    • Politics (6,447)
    • Science (5,855)
    • Technology (6,442)
    • Television (6,146)
    • US News (6,489)
    popular posts

    Arizona GOP Is About To Nominate A Secretary Of State Candidate To Help Trump Cheat In 2024

    [ad_1] Heading into Arizona’s primary, it is yet another Republican who claims not to believe…

    Los Angeles Fire Victims Benefit Show to Be Held at Intuit Dome

    January 10, 2025

    ‘911’ Renewed For Season 6 On Fox — New Episodes Ordered

    May 17, 2022

    1/6 Committee Has Bombshell Evidence Of GOP Guided Tours Before Attack

    May 20, 2022
    Archives
    Browse By Category
    • Books (1,592)
    • Business (6,481)
    • Events (85)
    • Film (6,453)
    • Lifestyle (4,504)
    • Music (6,587)
    • Politics (6,447)
    • Science (5,855)
    • Technology (6,442)
    • Television (6,146)
    • US News (6,489)
    About Us

    We are a creativity led international team with a digital soul. Our work is a custom built by the storytellers and strategists with a flair for exploiting the latest advancements in media and technology.

    Most of all, we stand behind our ideas and believe in creativity as the most powerful force in business.

    What makes us Different

    We care. We collaborate. We do great work. And we do it with a smile, because we’re pretty damn excited to do what we do. If you would like details on what else we can do visit out Contact page.

    Our Picks

    Elizabeth Hurley, 61, Wows In See-Through Red Dress With Billy Ray By Her Side

    November 18, 2026

    New Mystery and Thriller Books to Read | November 17 – NewInBooks

    November 17, 2026

    Mega Tours by Oasis, Dua Lipa and Coldplay Drive U.K. Musics Economic Contribution to Record-Highs

    November 17, 2026
    © 2026 New York Examiner News. All rights reserved. All articles, images, product names, logos, and brands are property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Terms & Conditions and Privacy Policy.

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
    Cookie SettingsAccept All
    Manage consent

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
    CookieDurationDescription
    cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
    cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
    cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
    cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
    cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
    viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
    Functional
    Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
    Performance
    Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
    Analytics
    Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
    Advertisement
    Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
    Others
    Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
    SAVE & ACCEPT